Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 1979452 | HLA-DR (HLA-DR) | bone marrow transplantation | NA | NA | NA | unclassified | |
| hla-dr, dq, and/or dp genotypic mismatches between recipient-donor pairs in unrelated bone marrow transplantation and transplant clinical outcome. | |||||||
| 1979452 | NA (NA) | bone marrow transplantation | NA | NA | NA | unclassified | |
| sixteen recipient-donor pairs who underwent unrelated bmt were analyzed for their hla-class ii identity by dna-rflp, in order to evaluate the importance of the genotypic hla-dr, dq, dp identity in the clinical outcome of unrelated bone marrow transplantation. | |||||||
| 1979452 | DP (HAPLOTYPE) | bone marrow transplantation | NA | NA | NA | unclassified | |
| sixteen recipient-donor pairs who underwent unrelated bmt were analyzed for their hla-class ii identity by dna-rflp, in order to evaluate the importance of the genotypic hla-dr, dq, dp identity in the clinical outcome of unrelated bone marrow transplantation. | |||||||
| 1979452 | HLA-DR (HLA-DR) | bone marrow transplantation | NA | NA | NA | unclassified | |
| sixteen recipient-donor pairs who underwent unrelated bmt were analyzed for their hla-class ii identity by dna-rflp, in order to evaluate the importance of the genotypic hla-dr, dq, dp identity in the clinical outcome of unrelated bone marrow transplantation. | |||||||
| 1985117 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| our assay can be used in hla genotypically identical bmt to detect a recipient-antidonor response, directed against cellularly defined mh antigens expressed on donor hpc, bmmnc, and pbl, before transplantation. | |||||||
| 1985117 | HLA (HLA) | bone marrow transplantation | NA | NA | NA | negation | |
| recipient-antidonor alloreactivity before hla genotypically identical bone marrow transplantation (bmt) between donor-recipient pairs that are negative in the mixed lymphocyte reaction (mlr), the cell-mediated lympholysis (cml) assay, and the lymphocyte crossmatch was not detectable in the majority of cases, using recipient peripheral blood lymphocytes (pbl) collected before bmt as responder cells and donor pbl as stimulator cells. | |||||||
| 1988712 | HLA (HLA) | transplantation | NA | NA | NA | positive+negation | |
| a comparison of this group with a control group similar in patient age and interval elapsed since transplantation revealed no significant differences in donor and recipient ages, degree of hla compatibility or serum creatinine levels. | |||||||
| 1989360 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| the actuarial probability for long term survival was found to be 67% after hla identical allogeneic sibling marrow transplantation. | |||||||
| 1989360 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| it is concluded that the serious prognosis for patients with saa has improved if the patients have the possibility for allogeneic hla identical family donor transplantation. | |||||||
| 1992610 | HLA (HLA) | transplantation | NA | cyclophosphamide | NA | unclassified | |
| neither the percentages nor the absolute numbers of host pbmc or gran were significantly affected by hla-matching, tbi dose-intensity, pretransplant remission status, subsequent development of acute or chronic graft-versus-host disease or relapse after transplantation. | |||||||
Copyright 2024